| efpeglenatide (HM11260C) / Hanmi |
NCT06174779: A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 420 | NA | HM11260C, Placebo | Hanmi Pharmaceutical Company Limited | Obesity | 12/25 | 07/26 | | |
| Pozenveo (poziotinib) / Assertio |
NCT05045404: Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 36 | NA | Poziotinib Hydrochloride, 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE | M.D. Anderson Cancer Center | Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 | 02/23 | 02/23 | | |
| Terminated | 2 | 648 | Europe, Canada, US, RoW | Poziotinib | Spectrum Pharmaceuticals, Inc | NSCLC | 04/23 | 04/23 | | |
|
|
|
|
|
|
|
|
| Terminated | 2 | 7 | US | Poziotinib | Spectrum Pharmaceuticals, Inc | NSCLC, Breast Cancer | 03/23 | 03/23 | | |
| Active, not recruiting | 2 | 93 | US | Poziotinib, HM781-36B, NOV120101 | M.D. Anderson Cancer Center, National Cancer Institute (NCI), Spectrum Pharmaceuticals, Inc | EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7 | 12/25 | 12/25 | | |
|
|
|
|
NCT04402008: Study of Poziotinib in Japanese Patients With NSCLC |
|
|
| Terminated | 1/2 | 42 | Japan | Poziotinib Once Daily Dosing, Poziotinib Twice Daily Dosing, Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1 | Spectrum Pharmaceuticals, Inc | NSCLC | 02/23 | 02/23 | | |
| poseltinib (HM71224) / Hanmi |
| Recruiting | 2 | 76 | RoW | Glofitamab, Poseltinib, Lenalidomide | Seoul National University Hospital | Relapsed/Refractory Diffuse Large B Cell Lymphoma | 11/25 | 11/26 | | |
| Rolvedon (eflapegrastim-xnst) / Assertio |
NEUTHREE, NCT05949333: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy |
|
|
| Recruiting | 4 | 100 | RoW | Eflapegrastim, Rolvedon, Eflapegrastim-xnst, HM-10460A, SPI-2012 | Eunseong Medical Foundation Good GANG-AN HOSPITAL, Hanmi Pharmaceutical Company Limited | Breast Neoplasms | 01/25 | 07/25 | | |
NCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy |
|
|
| Recruiting | 2 | 40 | US | Eflapegrastim, Rolontis®, SPI-2012, Chemotherapy | Spectrum Pharmaceuticals, Inc | Solid Tumors, Lymphoma | 10/27 | 10/27 | | |
NCT04187898: Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer |
|
|
| Active, not recruiting | 1 | 50 | US | Eflapegrastim, Docetaxel, Taxotere, Cyclophosphamide, Cytoxan | Spectrum Pharmaceuticals, Inc | Neutropenia, Breast Cancer | 07/24 | 07/24 | | |
| Oraxol (oral paclitaxel/encequidar) / Athenex |
| Not yet recruiting | 2 | 40 | Europe | Oraxol, HM30181AK-US, paclitaxel capsules, paclitaxel tablets, Tablet, Capsule, hard | Athenex, Inc., Athenex, Inc | Cancer patients for whom treatment with IV paclitaxel at 80 mg/m2 has been recommended by their oncologist, either as monotherapy or in combination with other agents, Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-002085-13: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
|
|
| Not yet recruiting | 2 | 43 | Europe | Oraxol, HM30181AK-US, paclitaxel capsules, Tablet, Capsule, hard | Athenex, Inc, Athenex, Inc | Study of Oraxol in Subjects with Cutaneous Angiosarcoma, Soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 48 | Europe, US, RoW | Oraxol, oral HM30181A + oral paclitaxel | Athenex, Inc. | Angiosarcoma of Skin | 05/23 | 05/23 | | |
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
|
|
| Recruiting | 2 | 5000 | US | Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole | QuantumLeap Healthcare Collaborative | Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer | 12/30 | 12/31 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT02970539: Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers |
|
|
| Active, not recruiting | 1b | 36 | US, RoW | Oraxol, oral HM30181AK-US tablet and paclitaxel capsule, Ramucirumab, LY3009806 | Athenex, Inc. | Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer | 03/19 | 12/22 | | |
ACTRN12614000365662: An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1 |
|
|
| Recruiting | 1 | 8 | | | Kinex Pharmaceuticals, Inc., Kinex Pharmaceuticals, Inc.
| Cancer | | | | |
ChiCTR1900021427: A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients |
|
|
| Not yet recruiting | 1 | 24 | | Drug therapy | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, sponsor | Breast Cancer | | | | |
| Terminated | 1 | 34 | US | Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda | Athenex, Inc., Merck Sharp & Dohme LLC | Solid Tumor | 05/23 | 05/23 | | |
|
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol |
|
|
| Terminated | 1 | 29 | Europe | Oraxol, Paclitaxel and HM30181AK-US | Athenex, Inc. | Solid Tumor, Adult | 05/23 | 05/23 | | |
| tirbanibulin oral (KX2-391 oral) / Hanmi, Athenex |
2021-004349-18: Long-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. Estudio de seguridad clínica a largo plazo para evaluar el riesgo de que la queratosis actínica (QA) progrese a cáncer de piel tras el tratamiento en cara o cuero cabelludo con tirbanibulina 10 mg/g pomada comparado con diclofenaco 3% gel en pacientes adultos. La tirbanibulina y el diclofenaco se usan para tratar adultos con QA en cara y cuero cabelludo. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar |
|
|
| Not yet recruiting | 4 | 540 | Europe | Solaraze 3% gel, Klisyri 10 mg/g unguento, [NA], Ointment, Gel, Klisyri 10 mg/g ointment, Solaraze 3%, gel | Almirall, S.A., Almirall SA, Almirall, S.A. | Actinic Keratosis on the Face or Scalp Queratosis actínica en la cara o el cuero cabelludo, Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2022-001251-16: Open phase IV study to assess the impact of tirbanibulin on the well-being of patients with actinic keratoses (TIRBASKIN). Estudio abierto de fase IV para evaluar el impacto de tirbanibulina en el bienestar de los pacientes con queratosis actínica (TIRBASKIN). |
|
|
| Ongoing | 4 | 420 | Europe | Tirbanibulin, M-14789-42, Ointment, Klisyri | Almirall, S.A., Almirall S.A. | Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Rosuzet (rosuvastatin/ezetimibe) / Hanmi, Merck (MSD) |
REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia |
|
|
| Recruiting | 4 | 240 | RoW | Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg) | Seoul National University Hospital, Gangnam Severance Hospital | Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias | 05/21 | 11/21 | | |
Rosuzet-IVUS, NCT03169985: Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque |
|
|
| Active, not recruiting | 4 | 280 | RoW | Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuzet tablet 10/10 mg, Rosuvastatin 20 mg orally once a day, Crestor tablet 10 mg | Samsung Medical Center, Hanmi Pharmaceutical co., ltd. | Coronary Artery Disease | 01/27 | 01/27 | | |
| Recruiting | 4 | 3548 | RoW | Ezetimibe 10mg + Rosuvastatin 5mg, Rosuzet 10/5 mg, Rosuvastatin 20mg, Crestor 20mg | Kiyuk Chang, MD,PhD | Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity | 01/24 | 07/24 | | |
| belvarafenib (RG6185) / Hanmi |
| Recruiting | 2 | 920 | Europe, Canada, Japan, US, RoW | Entrectinib, Rozlytrek, Alectinib, Alecensa, Atezolizumab, Tecentriq, Ipatasertib, Trastuzumab emtansine, Kadcyla, Idasanutlin, Inavolisib, GDC-0077, Belvarafenib, Pralsetinib, Gavreto (US), GDC-6036, Camonsertib | Hoffmann-La Roche | Solid Tumors | 09/32 | 09/32 | | |
NCT04835805: A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. |
|
|
| Active, not recruiting | 1 | 65 | Europe, Canada, US, RoW | Belvarafenib, Cobimetinib, Nivolumab | Genentech, Inc. | Melanoma | 11/25 | 11/25 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
| efinopegdutide (HM12525A) / Merck (MSD) |
2020-005136-30: A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease |
|
|
| Ongoing | 2 | 130 | Europe | Efinopegdutide, MK-6024, Solution for injection in pre-filled syringe, Solution for injection in pre-filled pen, Ozempic® | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT06465186: A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) |
|
|
| Not yet recruiting | 2 | 80 | NA | Efinopegdutide, MK-6024, Placebo | Merck Sharp & Dohme LLC | Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis | 05/26 | 05/26 | | |
MK-6024-013, NCT05877547: A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 300 | Europe, Canada, Japan, US, RoW | Efinopegdutide, MK-6024, HM12525A, JNJ-64565111, Semaglutide, Wegovy, Placebo | Merck Sharp & Dohme LLC | Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | 12/25 | 12/25 | | |
| Recruiting | 1 | 24 | US | Efinopegdutide, MK-6024, HM12525A, JNJ-64565111 | Merck Sharp & Dohme LLC | Non-alcoholic Steatohepatitis, Hepatic Impairment | 08/24 | 08/24 | | |
| tuspetinib (HM43239) / Aptose Biosci |
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 218 | Europe, US, RoW | Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax | Aptose Biosciences Inc. | Relapsed or Refractory Acute Myeloid Leukemia | 02/24 | 08/24 | | |
| efocipegtrutide (HM15211) / Hanmi |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/25 | 11/25 | | |
| tivumecirnon (FLX475) / RAPT Therap |
| Completed | 2 | 20 | RoW | FLX475, Pembrolizumab, Keytruda | Hanmi Pharmaceutical Company Limited, Merck Sharp & Dohme LLC | Gastric Cancer | 10/23 | 10/23 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
| HCP1803 / Hanmi |
| Completed | 3 | 361 | RoW | HCP1803-3, RLD2002, HPP2003-3, HPP2004 | Hanmi Pharmaceutical Company Limited | Hypertension | 06/23 | 06/23 | | |
HM_APOLLO, NCT06438172: A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension |
|
|
| Recruiting | 3 | 220 | RoW | HCP1803-3, RLD2001-1, HPP2003-3, HPP2002-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 06/25 | 06/25 | | |
NCT05723549: A Study to Evaluate the PK, Safety and Tolerability of HCP1803. |
|
|
| Completed | 1 | 20 | RoW | HCP1803-3, RLD2002, HCP1904-1 | Hanmi Pharmaceutical Company Limited | Healthy | 03/23 | 03/23 | | |
| HM15136 / Hanmi |
2021-000508-39: A study to Evaluate the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of HM15136 administered in pediatric Patients with Congenital Hyperinsulinism (CHI) |
|
|
| Not yet recruiting | 2 | 16 | Europe | HM15136, Solution for injection in pre-filled syringe | Hanmi Pharm. Co., Ltd., Hanmi Pharm. Co., Ltd. | Congenital Hyperinsulinism (CHI), Congenital hyperinsulinism is a disorder associated with severe, persistent hypoglycemia, characterized by excessive and dysregulated insulin secretion by the pancreatic β-cells., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04732416: HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) |
|
|
| Recruiting | 2 | 16 | Europe, US, RoW | HM15136 | Hanmi Pharmaceutical Company Limited | Congenital Hyperinsulinism | 03/25 | 03/25 | | |
| HM15912 / Hanmi |
2021-000176-11: Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure |
|
|
| Ongoing | 2 | 18 | Europe | HM15912 (LAPS GLP-2 analog), HM15912 (LAPS GLP-2 analog), Solution for injection in pre-filled syringe | Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd. | Short Bowel Syndrome-associated Intestinal Failure (SBS-IF), Short bowel length. With intestinal failure, the length and function of the small intestine falls below the minimum necessary for the absorption of nutrients and water to maintain good health., Diseases [C] - Digestive System Diseases [C06] | | | | |
| Recruiting | 2 | 18 | Europe, US, RoW | HM15912 Active, Placebo | Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd. | Short Bowel Syndrome | 12/25 | 12/25 | | |
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function |
|
|
| Completed | 1 | 16 | US | HM15912 | Hanmi Pharmaceutical Company Limited | Renal Impairment | 08/23 | 08/23 | | |
| fidasimtamab (IBI315) / Hanmi, Innovent Biologics |
NCT05608785: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes |
|
|
| Not yet recruiting | 1/2 | 45 | NA | IBI315, Oxaliplatin, Capecitabine, TST001, TQB2450, Anrotinib | Henan Cancer Hospital | Gastric Cancer, Gastroesophageal-junction Cancer | 12/23 | 10/24 | | |
NCT04162327: A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor |
|
|
| Completed | 1a/1b | 55 | RoW | IBI315 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Solid Tumor | 01/22 | 06/23 | | |
| Klisyri (tirbanibulin ointment) / Hanmi, Almirall, Athenex, PharmaEssentia |
2022-003326-44: SunDamage: Tirbanibulin salve for the treatment of chronically sun-damaged skin on the face |
|
|
| Ongoing | 4 | 20 | Europe | Klisyri, Ointment, Klisyri® (Tirbanibulin) | Medizinische Universität Graz, Universitätsklinik für Dermatologie und Venerologie, Almirall GmbH | Subclinical lesions in UV-exposed areas of chronically UV-damaged skin in the face adjacent to lesions caused by actinic keratosis but not obviously affected themselves., Facial skin areas chronically damaged by sunlight (UV light), Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 4 | 342 | Europe | Tirbanibulin 2.5 mg ointment | Almirall, S.A., Almirall S.A. | Actinic Keratosis | 12/23 | 12/23 | | |
| Completed | 4 | 22 | Europe | Tirbanibulin | Medical University of Graz | Actinic Keratosis | 11/23 | 11/23 | | |
NCT06026358: Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands |
|
|
| Withdrawn | 4 | 30 | NA | Tirbanibulin | Medical University of Graz, Almirall, SAS | Actinic Keratoses | 12/24 | 12/24 | | |
NCT05387525: A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp |
|
|
| Recruiting | 4 | 450 | Europe | Tirbanibulin (Klisyri®) 10 mg/g ointment, Klisyri®, Diclofenac Sodium 3% Gel | Almirall, S.A. | Keratosis, Actinic | 03/27 | 03/27 | | |
NCT05231044: A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp |
|
|
| Completed | 3 | 108 | Japan | KX01 ointment 1%, Placebo | PharmaEssentia, PharmaEssentia Japan K.K. | Actinic Keratosis | 11/23 | 11/23 | | |
TirbAKare, NCT06135415: A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis |
|
|
| Recruiting | 3 | 270 | Europe | Tirbanibulin, Klisyri®, Vehicle ointment | Almirall, S.A. | Keratosis, Actinic | 12/24 | 12/24 | | |
NCT05713760: Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults |
|
|
| Recruiting | 2 | 10 | US | Tirbanibulin Ointment 1%, Klisyri (tirbanibulin ointment 1%) | Austin Institute for Clinical Research | Superficial Basal Cell Carcinoma | 12/23 | 04/24 | | |
PROAK, NCT05260073: Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis |
|
|
| Completed | N/A | 300 | US | Tirbanibulin (Klisyri®) | Almirall, S.A. | Keratosis, Actinic | 10/22 | 03/23 | | |
| HCP1904 / Hanmi |
NCT04830449: Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients |
|
|
| Completed | 3 | 122 | RoW | HCP1904-2, RLD2001-2 | Hanmi Pharmaceutical Company Limited | Hypertension | 08/21 | 08/21 | | |
NCT04820907: Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients |
|
|
| Completed | 3 | 123 | RoW | HCP1904-1, RLD2001-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 09/21 | 09/21 | | |
NCT05199129: Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients |
|
|
| Completed | 3 | 166 | RoW | HCP1904-3, RLD2001-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 09/22 | 09/22 | | |
NCT05407220: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers. |
|
|
| Not yet recruiting | 1 | 16 | RoW | HCP1904-1, HCP1904-3 | Hanmi Pharmaceutical Company Limited | Healthy | 07/22 | 07/22 | | |
| BH3120 / Hanmi |
NCT06234397: Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 191 | US, RoW | BH3120 | Hanmi Pharmaceutical Company Limited | Advanced or Metastatic Solid Tumors | 02/27 | 07/27 | | |
| HIP2105 / Hanmi |
NCT04975711: Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers |
|
|
| Completed | 1 | 48 | RoW | HIP2105, RLD2104 | Hanmi Pharmaceutical Company Limited | Healthy Volunteer | 11/21 | 11/21 | | |
| HCP2102 / Hanmi |
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients |
|
|
| Completed | 3 | 249 | RoW | HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2 | Hanmi Pharmaceutical Company Limited | Hypertension | 12/23 | 12/23 | | |
| HM97662 / Hanmi |
NCT05598151: Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 140 | RoW | HM97662 | Hanmi Pharmaceutical Company Limited | Advanced or Metastatic Solid Tumors | 02/25 | 06/28 | | |
| HM99462 / Hanmi |
| No trials found |
| HM16390 / Hanmi |
| No trials found |
| HM90822 / Hanmi |
| No trials found |
| 27 / Hanmi |
| No trials found |
